```
=> s (antibod? or antagonist? or block? or inhibit? or neutral?)(s)((interleukin or
il)(w)22)
   4 FILES SEARCHED...
L1          212 (ANTIBOD? OR ANTAGONIST? OR BLOCK? OR INHIBIT? OR NEUTRAL?)(S)((
                INTERLEUKIN OR IL)(W) 22)

=> s ((interleukin or il)(w)22)(p)(arthriti? or osteaoarthrit?)
L2           94 ((INTERLEUKIN OR IL)(W) 22)(P)(ARTHRITI? OR OSTEAOARTHRIT?)

=> s l1 and l2
L3           57 L1 AND L2

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4            51 DUP REM L3 (6 DUPLICATES REMOVED)

=> s l4 and py<=2003
   1 FILES SEARCHED...
   3 FILES SEARCHED...
L5           34 L4 AND PY<=2003

=> d ibib abs 1-34

L5   ANSWER 1 OF 34  SCISEARCH  COPYRIGHT (c) 2005 The Thomson Corporation  on
     STN
ACCESSION NUMBER:    2003:234755  SCISEARCH
THE GENUINE ARTICLE: 654EV
TITLE:               IL-22 inhibitors to treat
                     inflammatory disorders such as arthritis
AUTHOR:              ANON
SOURCE:              EXPERT OPINION ON THERAPEUTIC PATENTS, (MAR 2003
     )               Vol. 13, No. 3, pp. 373-375.
                     Publisher: ASHLEY PUBLICATIONS LTD, UNITEC HOUSE, 3RD FL,
                     2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND.
                     ISSN: 1354-3776.
DOCUMENT TYPE:       Article; Journal
LANGUAGE:            English
REFERENCE COUNT:     13
                    *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
AB       IL-22 is a recently described cytokine showing 23%
     amino acid identity with IL-10, and which has been previously shown to
     induce the production of acute phase proteins in liver and pancreas,
     suggesting a role in inflammatory responses. This patent application
     claims agents that modulate IL-22 activity useful as
     modulators of a large panel of inflammatory disorders, including
     autoimmune diseases, cancer and sepsis. More particularly, anti-IL
     -22 antibodies are reported to inhibit
     arthritis in a mouse model.

L5   ANSWER 2 OF 34  BIOSIS  COPYRIGHT (c) 2005 The Thomson Corporation  on STN
ACCESSION NUMBER:    2003:585284  BIOSIS
DOCUMENT NUMBER:     PREV200300586194
TITLE:               An anti-murine IL-22 monoclonal
                     antibody decreases disease severity in a murine
                     model of collagen induced arthritis.
AUTHOR(S):           Resmini, Christine [Reprint Author]; Shields, Kathleen M.
                     [Reprint Author]; Lambert, Andre-Jean [Reprint Author];
                     Wong, Anthony [Reprint Author]; Pednault, Glen [Reprint
                     Author]; Hegen, Martin [Reprint Author]; Fouser, Lynette A.
                     [Reprint Author]; Pittman, Debra D. [Reprint Author]
CORPORATE SOURCE:    Wyeth Research, 87 CambridgePark Drive, Cambridge, MA,
                     02140, USA
```

SOURCE: European Cytokine Network, (Sept 2003) Vol. 14, No. Supplement 3, pp. 129. print.
Meeting Info.: Annual Meeting of the International Cytokine Society. Dublin, Ireland. September 20-24, 2003.
ISSN: 1148-5493.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Dec 2003
Last Updated on STN: 10 Dec 2003

L5 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:160628 CAPLUS
TITLE: **Antibodies** against **interleukin-22** and uses therefor
INVENTOR(S): Li, Jing; Tan, Xiang-yang; Tomkinson, Kathleen N.; Pittman, Debra D.; Veldman, Geertruida M.; Fouser, Lynette
PATENT ASSIGNEE(S): Genetics Institute, Llc, USA
SOURCE: U.S. Pat. Appl. Publ., 59 pp., Cont.-in-part of U.S. Ser. No. 84,298.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 2005042220	A1	20050224	US 2004-873972		20040622	
US 2003099649	A1	20030529	US 2002-84298		20020225	<--
US 2003157106	A1	20030821	US 2002-256977		20020927	<--
PRIORITY APPLN. INFO.:			US 2001-270823P	P	20010223	
			US 2001-281353P	P	20010403	
			US 2002-84298	A2	20020225	
			US 2003-480652P	P	20030623	
			US 1999-131473P	P	19990428	
			US 2000-561811	A1	20000428	

AB **Antibodies** and antigen-binding fragments thereof that bind **interleukin-22** (**IL-22**), in particular, human **IL-22**, and their uses in regulating **IL-22**-associated immune responses are disclosed. The **antibodies** disclosed herein are useful in diagnosing, preventing, or treating **IL-22**-associated immune disorders, e.g., autoimmune disorders (e.g., **arthritis**).

L5 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:676061 CAPLUS
DOCUMENT NUMBER: 137:215818
TITLE: **Antibodies** specific to **interleukin 22** for treating inflammatory disorders
INVENTOR(S): Jacobs, Kenneth; Pittman, Debra; Fouser, Lynette; Spaulding, Vikki; Xuan, Dejun
PATENT ASSIGNEE(S): Genetics Institute, LLC, USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002068476	A2	20020906	WO 2002-US5684	20020225 <--
WO 2002068476	A3	20030807		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2438238	AA	20020906	CA 2002-2438238	20020225 <--
EP 1373319	A2	20040102	EP 2002-721152	20020225

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2003157106	A1	20030821	US 2002-256977	20020927 <--
PRIORITY APPLN. INFO.:			US 2001-270823P	P 20010223
			US 2001-281353P	P 20010403
			US 1999-131473P	P 19990428
			US 2000-561811	A1 20000428
			US 2002-84298	A1 20020225
			WO 2002-US5684	W 20020225

AB **Inhibitors** of **IL-22** are disclosed as well as pharmaceutical compns. and methods of using same. The **IL-22 inhibitors** include polyclonal, monoclonal, **neutralizing**, and humanized **antibodies**, or their fragments. These antibodies are useful for treating inflammatory disorders including septicemia, autoimmune diseases, acute phase responses, infections, rheumatoid **arthritis**, osteoarthritis, multiple sclerosis, myasthenia gravis, inflammatory bowel disease, lupus, diabetes mellitus, psoriasis, wound healing, free radical injury, ischemia, atherosclerosis, allergy and cancer.

L5 ANSWER 5 OF 34 USPATFULL on STN

ACCESSION NUMBER:	2003:265372 USPATFULL
TITLE:	Interleukins-21 and 22
INVENTOR(S):	Ebner, Reinhard, Gaithersburg, MD, UNITED STATES Ruben, Steven M., Brookeville, MD, UNITED STATES
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003186387	A1	20031002	<--
APPLICATION INFO.:	US 2003-397282	A1	20030327 (10)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-731816, filed on 8 Dec 2000, PENDING Continuation of Ser. No. US 1999-320713, filed on 27 May 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169837P	19991209 (60)
	US 1998-87340P	19980529 (60)
	US 1998-99805P	19980910 (60)
	US 1999-131965P	19990430 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS:	28

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 8177
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human proteins designated Interleukin-21 (IL-21) and **Interleukin-22** (**IL-22**), and isolated polynucleotides encoding these proteins. Also provided are vectors, host cells, **antibodies**, and recombinant methods for producing these human proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, and/or preventing disorders related to these novel human proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 34 USPATFULL on STN
ACCESSION NUMBER: 2003:226287 USPATFULL
TITLE: Isolated cytokine receptor LICR-2
INVENTOR(S): Renauld, Jean-Christophe, Brussels, BELGIUM
Fickenscher, Helmut, Erlangen-Nurnberg, GERMANY, FEDERAL REPUBLIC OF
Dumoutier, Laure, Brussels, BELGIUM
Hor, Simon, Erlangen-Nurnberg, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003158100	A1	20030821	<--
APPLICATION INFO.:	US 2001-26106	A1	20011221	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
LINE COUNT: 1542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to new members of the Class II cytokine receptor family, such as LICR-2. The new member binds to AK155, and mediates STAT activation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 34 USPATFULL on STN
ACCESSION NUMBER: 2003:225295 USPATFULL
TITLE: Composition and method for treating inflammatory disorders
INVENTOR(S): Jacobs, Kenneth, Newton, MA, UNITED STATES
Pittman, Debra D., Windham, NH, UNITED STATES
Fouser, Lynette, Acton, MA, UNITED STATES
Spaulding, Vikki, Lowell, MA, UNITED STATES
Xuan, Dejun, Chestnut Hill, MA, UNITED STATES
PATENT ASSIGNEE(S): Wyeth, Madison, NJ, UNITED STATES, 07940 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003157106	A1	20030821	<--
APPLICATION INFO.:	US 2002-256977	A1	20020927	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-84298, filed on 25 Feb 2002, PENDING Continuation of Ser. No. US 2000-561811, filed on 28 Apr 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-270823P	20010223 (60)
	US 2001-281353P	20010403 (60)
	US 1999-131473P	19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3109
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Inhibitors** of **IL-22** are disclosed as well as pharmaceutical compositions and methods of using same. The **inhibitors** include **IL-22 antibodies** and are useful for treating inflammatory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 34 USPATFULL on STN
ACCESSION NUMBER: 2003:158936 USPATFULL
TITLE: Methods and compositions for modulating interleukin-21 receptor activity
INVENTOR(S): Carter, Laura, Medford, MA, UNITED STATES
Carreno, Beatriz, Acton, MA, UNITED STATES
Lowe, Leslie D., Sudbury, MA, UNITED STATES
Whitters, Matthew J., Hudson, MA, UNITED STATES
Dunussi, Kyri, Belmont, MA, UNITED STATES
Collins, Mary, Natick, MA, UNITED STATES
Ma, Margery, Roxbury, MA, UNITED STATES
Young, Deborah A., Melrose, MA, UNITED STATES
Witek, JoAnn S., Acton, MA, UNITED STATES
Larsen, Glenn, Sudbury, MA, UNITED STATES
Kasaian, Marion T., Charlestown, MA, UNITED STATES
Donaldson, Debra D., Medford, MA, UNITED STATES
Unger, Michelle, Chapel Hill, NC, UNITED STATES
PATENT ASSIGNEE(S): Wyeth, Madison, NJ (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003108549	A1	20030612	<--
APPLICATION INFO.:	US 2002-264634	A1	20021004 (10)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-972218, filed on 4 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2000-569384, filed on 11 May 2000, PENDING Continuation-in-part of Ser. No. US 2000-560766, filed on 28 Apr 2000, ABANDONED Continuation of Ser. No. US 1998-40005, filed on 17 Mar 1998, GRANTED, Pat. No. US 6057128

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373746P	20020417 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 47 Drawing Page(s)
LINE COUNT: 4944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ("IL-21R" or "MU-1"), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 34 USPATFULL on STN
ACCESSION NUMBER: 2003:145905 USPATFULL
TITLE: Composition and method for treating inflammatory disorders
INVENTOR(S): Jacobs, Kenneth, Newton, MA, UNITED STATES
Pittman, Debra D., Windham, NH, UNITED STATES
Fouser, Lynette, Acton, MA, UNITED STATES
Spaulding, Vikki, Lowell, MA, UNITED STATES
Xuan, Dejun, Chestnut Hill, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003099649	A1	20030529	<--
APPLICATION INFO.:	US 2002-84298	A1	20020225	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-270823P	20010223 (60)
	US 2001-281353P	20010403 (60)
	US 1999-131473P	19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 3007
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Inhibitors** of **IL-22** are disclosed as well as pharmaceutical compositions and methods of using same. The **inhibitors** include **IL-22 antibodies** and are useful for treating inflammatory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 34 USPATFULL on STN
ACCESSION NUMBER: 2003:134048 USPATFULL
TITLE: Interleukins-21 and 22
INVENTOR(S): Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003092133	A1	20030515	<--
APPLICATION INFO.:	US 2002-153770	A1	20020524 (10)	

RELATED APPLN. INFO.: Division of Ser. No. US 1999-320713, filed on 27 May 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-87340P	19980529 (60)
	US 1998-99805P	19980910 (60)
	US 1999-131965P	19990430 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 6571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human proteins designated Interleukin-21 (IL-21) and **Interleukin-22** (**IL-22**), and isolated polynucleotides encoding these proteins. Also provided are vectors, host cells, **antibodies**, and recombinant methods for producing these human proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 34 USPATFULL on STN
ACCESSION NUMBER: 2003:3510 USPATFULL
TITLE: INTERLEUKINS-21 AND 22
INVENTOR(S): EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003003545	A1	20030102	<--
APPLICATION INFO.:	US 1999-320713	A1	19990527 (9)	

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-87340P	19980529 (60)
	US 1998-99805P	19980910 (60)
	US 1999-131965P	19990430 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 6117
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human proteins designated Interleukin-21 (IL-21) and **Interleukin-22** (**IL-22**), and isolated polynucleotides encoding these proteins. Also provided are vectors, host cells, **antibodies**, and recombinant methods for producing these human proteins. The

invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 34 USPATFULL on STN
ACCESSION NUMBER: 2001:160802 USPATFULL
TITLE: Interleukins-21 and 22
INVENTOR(S): Ebner, Reinhard, Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001023070	A1	20010920	<--
APPLICATION INFO.:	US 2000-731816	A1	20001208 (9)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-320713, filed on 27 May 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US11644, filed on 27 May 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-87340P	19980529 (60)
	US 1999-131965P	19990430 (60)
	US 1999-169837P	19991209 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 7740
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human proteins designated Interleukin-21 (IL-21) and **Interleukin-22** (**IL-22**), and isolated polynucleotides encoding these proteins. Also provided are vectors, host cells, **antibodies**, and recombinant methods for producing these human proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, and/or preventing disorders related to these novel human proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003090694 PCTFULL ED 20031117 EW 200345
TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTO IMMUNE AND CHRONIC INFLAMMATORY DISEASES
TITLE (FRENCH): METHODES ET COMPOSITIONS POUR DIAGNOSTIQUER ET CONTROLER DES MALADIES INFLAMMATOIRES AUTO-IMMUNES ET CHRONIQUES
INVENTOR(S): WOHLGEMUTH, Jay, 1165 Monte Rosa Drive, Menlo Park, CA 94025, US [US, US];
FRY, Kirk, 2604 Ross Road, Palo Alto, CA 94303, US [US, US];
WOODWARD, Robert, 1828 Rheem Court, Pleasanton, CA 94588, US [US, US];
LY, Ngoc, 2000 Crystal Springs Road 15-14, San Bruno, CA 94066, US [US, US]
PATENT ASSIGNEE(S): EXPRESSION DIAGNOSTICS, INC., 384 Oyster Point Boulevard, Suite No. 6, South San Francisco, CA 94080,

US [US, US], for all designates States except US;
WOHLGEMUTH, Jay, 1165 Monte Rosa Drive, Menlo Park, CA 94025, US [US, US], for US only;
FRY, Kirk, 2604 Ross Road, Palo Alto, CA 94303, US [US, US], for US only;
WOODWARD, Robert, 1828 Rheem Court, Pleasanton, CA 94588, US [US, US], for US only;
LY, Ngoc, 2000 Crystal Springs Road 15-14, San Bruno, CA 94066, US [US, US], for US only

AGENT: LITTLEFIELD, Otis, B.$, Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003090694	**A2**	**20031106**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2003-US13015 A 20030424
PRIORITY INFO.: 2002-10/131,827 20020424
US 2002-10/131,827 20020424

ABEN Methods of diagnosing or monitoring auto immune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring auto immune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis and kits or systems containing the same are also described.

ABFR L'invention concerne des methodes et des compositions pour diagnostiquer et controler, chez un patient, des maladies inflammatoires auto-immunes et chroniques, en particulier le lupus erythemateux systemique et l'arthrite rhumatoide, par detection du niveau d'expression d'un ou de plusieurs genes chez ledit patient. L'invention concerne en outre des oligonucleotides de diagnostic destines a diagnostiquer et controler des maladies inflammatoires auto-immunes et chroniques, en particulier le lupus erythemateux systemique et l'arthrite rhumatoide, et des trousses ou systemes contenant ces oligonucleotides.

L5 ANSWER 14 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003089569 PCTFULL ED 20031105 EW 200344
TITLE (ENGLISH): USE OF IL-19, IL-22 AND IL-24 TO TREAT HEMATOPOIETIC DISORDERS
TITLE (FRENCH): UTILISATION D'IL-19, D'IL-22 ET D'IL-24 POUR LE TRAITEMENT DES TROUBLES HEMATOPOIETIQUES
INVENTOR(S): ROWLINSON, Scott, William, 7918 Cove Trace Court, Indianapolis, IN 46256, US [AU, US]
PATENT ASSIGNEE(S): ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, IN 46285, US [US, US], for all designates States except US;
ROWLINSON, Scott, William, 7918 Cove Trace Court,

Indianapolis, IN 46256, US [AU, US], for US only
AGENT: WISKERCHEN, MaryAnn$, Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003089569	**A2**	**20031030**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-US31599 A 20021024
PRIORITY INFO.: 2001-60/332,986 20011106
US 2001-60/332,986 20011106

ABEN The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders.
ABFR L'invention concerne un procede relatif a l'utilisation d'une sequence de genes mammaliens et de polypeptides codes par cette sequence pour le traitement de troubles hematopoietiques chez des mammiferes.

L5 ANSWER 15 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003083062 PCTFULL ED 20031027 EW 200341
TITLE (ENGLISH): ANTI-IL-TIF ANTIBODIES AND METHODS OF USING IN INFLAMMATION
TITLE (FRENCH): ANTICORPS ANTI-IL-TIF ET LEURS METHODES D'UTILISATION DANS UNE INFLAMMATION
INVENTOR(S): XU, Wenfeng, 12432 54th Avenue West, Mukilteo, WA 98275, US;
KINDSVOGEL, Wayne, 6014 24th Avenue NE, Seattle, WA 98115, US;
HUGHES, Steven, D., 3610 NE 65th Street, Seattle, WA 98115, US;
CHANDRASEKHER, Yasmin, A., 5912 83rd Place SE, Mercer Island, WA 98040, US
PATENT ASSIGNEE(S): ZYMOGENETICS, INC., 1201 Eastlake Avenue East, Seattle, WA 98102, US [US, US]
AGENT: JOHNSON, Jennifer, K.$, ZymoGenetics, Inc., 1201 Eastlake Ave E, Seattle, WA 98102$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003083062	**A2**	**20031009**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2003-US9075 A 20030324
PRIORITY INFO.: 2002-60/366,842 20020322
US 2002-60/366,842 20020322

ABEN The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.

ABFR L'invention concerne le blocage de l'activite des molecules polypeptidiques IL-TIF, IL-TIF etant une cytokine impliquee dans des processus inflammatoires et des maladies humaines. L'invention concerne des anticorps anti-IL-TIF et des partenaires de liaison ainsi que des methodes d'antagonisation d'IL-TIF utilisant entre autres lesdits anticorps et partenaires de liaison dans des maladies inflammatoires humaines induites par IL-TIF.

L5 ANSWER 16 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003075952 PCTFULL ED 20030926 EW 200338
TITLE (ENGLISH): METHODS OF ENHANCING IMMUNE INDUCTION INVOLVING MDA-7
TITLE (FRENCH): PROCEDES D'AMELIORATION DE L'INDUCTION DE LA REPONSE IMMUNITAIRE IMPLIQUANT MDA-7

INVENTOR(S): CHADA, Sunil, 4007 Waterview Court, Missouri City, TX 77459, US [US, US];
PATAER, Abujiang, 8181 Fannin Street Apt. #2026, Houston, TX 77054, US [CN, US];
RAMESH, Rajagopal, 2027 Cypress Bend Lane, Sugar Land, TX 77478, US [IN, US];
MHASHILKAR, Abner, 12414 Tottenham Dr., Houston, TX, US [IN, US];
ROTH, Jack, 6516 Brompton Road, Houston, TX 77005, US [US, US];
SWISHER, Steve, 1911 Mossback Circle, Fresno, TX 77545, US [US, US]
PATENT ASSIGNEE(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, 201 West 7th.St., Austin, TX 78701, US [US, US], for all designates States except US;
INTROGEN THERAPEUTICS, INC., 301 Congress Avenue, Suite 1850, Austin, TX 78701, US [US, US], for all designates States except US;
CHADA, Sunil, 4007 Waterview Court, Missouri City, TX 77459, US [US, US], for US only;
PATAER, Abujiang, 8181 Fannin Street Apt. #2026, Houston, TX 77054, US [CN, US], for US only;
RAMESH, Rajagopal, 2027 Cypress Bend Lane, Sugar Land, TX 77478, US [IN, US], for US only;
MHASHILKAR, Abner, 12414 Tottenham Dr., Houston, TX, US [IN, US], for US only;
ROTH, Jack, 6516 Brompton Road, Houston, TX 77005, US [US, US], for US only;
SWISHER, Steve, 1911 Mossback Circle, Fresno, TX 77545, US [US, US], for US only
AGENT: SHISHIMA, Gina, N.$, Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX 78701$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2003075952	**A1**	**20030918**

DESIGNATED STATES

W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2003-US6489	A	20030303
PRIORITY INFO.:	2002-60/361.755		20020305
	US 2002-60/361.755		20020305
	US 2002-60/370.335		20020405
	US 2002-60/370.335		20020405
	US 2002-60/404.932		20020821
	US 2002-60/404.932		20020821

ABEN The present invention relates to compositions and methods for the enhancing or inducing an immune response against an immunogenic molecule by indirectly activating PKR. More specifically, immunotherapy is improved by co-administering a MDA-7 polypeptide with an immunogenic molecule against which an immune response is desired. Such immunotherapies include cancer vaccines, and compositions thereof are described.

ABFR L'invention porte sur des compositions et des procedes permettant d'ameliorer ou d'induire une reponse immunitaire contre une molecule immunogene par activation indirecte de PKR. Plus particulierement, l'immunotherapie est amelioree par co-administration d'un polypeptide MDA-7 avec une molecule immunogene contre laquelle une reponse immunitaire est voulue. Ces immunotherapies comprennent des vaccins contre le cancer, et des compositions correspondantes.

L5 ANSWER 17 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN

ACCESSION NUMBER:	2003070744 PCTFULL ED 20030904 EW 200335
TITLE (ENGLISH):	RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
TITLE (FRENCH):	INHIBITION INDUITE PAR INTERFERENCE ARN DE L'EXPRESSION DU GENE DE L'INTERLEUKINE AU MOYEN D'ACIDES NUCLEIQUES INTERFERENTS COURTS (SINA)
INVENTOR(S):	MCSWIGGEN, James, 4866 Franklin Drive, Boulder, CO 80301, US [US, US]; BEIGELMAN, Leonid, 5530 Colt Drive, Longmont, CO 80503, US [US, US]; THOMPSON, James, 705 Barberry Circle, Lafayette, CO 80026, US [US, US]
PATENT ASSIGNEE(S):	RIBOZYME PHARMACEUTICALS, INC., 2950 Wilderness Place, Boulder, CO 80301, US [US, US], for all designates States except US; MCSWIGGEN, James, 4866 Franklin Drive, Boulder, CO 80301, US [US, US], for US only; BEIGELMAN, Leonid, 5530 Colt Drive, Longmont, CO 80503, US [US, US], for US only; THOMPSON, James, 705 Barberry Circle, Lafayette, CO 80026, US [US, US], for US only
AGENT:	TERPSTRA, Anita, J.$, McDonnell Boehnen Hulbert & Berghoff, Suite 3200, 300 South Wacker Drive, Chicago,

IL 60606$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003070744	**A1**	**20030828**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2003-US4566	A	20030211
PRIORITY INFO.:	2002-60/358,580		20020220
	US 2002-60/358,580		20020220
	US 2002-60/363,124		20020311
	US 2002-60/363,124		20020311
	US 2002-60/386,782		20020606
	US 2002-60/386,782		20020606
	US 2002-60/406,784		20020829
	US 2002-60/406,784		20020829
	US 2002-60/408,378		20020905
	US 2002-60/408,378		20020905
	US 2002-60/409,293		20020909
	US 2002-60/409,293		20020909
	US 2003-60/440,129		20030115
	US 2003-60/440,129		20030115

ABEN The present invention concerns methods and reagents useful in modulating interleukin gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against interleukin (e.g., IL-1, IL-2, IL-5, IL-6, IL-10, IL-15, IL-16, IL-17 and IL-18 genes and genes encoding interleukin receptors of IL-1, IL-2, IL-5, IL-6, IL-10, IL-15, Il-16, IL-17 and IL-18) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of transplant rejection, autoimmune disease, inflammatory disease, infectous disease, allergy, and any other condition that responds to modulation of interleukin expression or activity.

ABFR L'invention concerne des procedes et des reactifs utiles dans la modulation de l'expression du gene de l'interleukine dans une pluralite d'applications, notamment l'utilisation dans des applications therapeutiques, diagnostiques, de validation de cible et de decouverte genomique. Plus precisement, l'invention concerne des petites molecules d'acides nucleiques, telles que des acides nucleiques interferents courts (siNA), des ARN interferents courts (siRNA), des ARN bicatenaires (dsRNA), des micro-ARN (miRNA) et des molecules d'ARN courts a structure en epingle a cheveux (shRNA) capables d'induire une interference ARN (RNAi) contre l'expression et/ou l'activite du gene de l'interleukine (par exemple, les genes IL-1, IL-2, IL-5, IL-6, IL-10, IL-15, IL-16, IL-17 et IL-18 et des genes codant des recepteurs de l'interleukine de IL-1, IL-2, IL-5, IL-6, IL-10, IL-15, Il-16, IL-17 et IL-18). Les

petites molecules d'acides nucleiques sont utiles dans le traitement du rejet du greffon, de maladies auto-immunes, de maladies inflammatoires, de maladies infectieuses, d'allergies et d'autres etats quelconques repondant a la modulation de l'expression ou de l'activite de l'interleukine.

L5 ANSWER 18 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003057732 PCTFULL ED 20030723 EW 200329
TITLE (ENGLISH): TARGETED LIGANDS
TITLE (FRENCH): LIGANDS CIBLES
INVENTOR(S): HERMAN, William, 18 Gailcrest Circle, Thornhill, Ontario L4J 5V2, CA [CA, CA]
PATENT ASSIGNEE(S): HERMAN, William, 18 Gailcrest Circle, Thornhill, Ontario L4J 5V2, CA [CA, CA]
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003057732	**A2**	**20030717**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2003-CA44	A	20030114
PRIORITY INFO.:	2002-2,368,708		20020114
	CA 2002-2,368,708		20020114
	CA 2002-PCT/CA02/00317		20020311
	CA 2002-PCT/CA02/00317		20020311
	CA 2002-2,397,169		20020813
	CA 2002-2,397,169		20020813
	CA 2002-2,402,930		20020919
	CA 2002-2,402,930		20020919

ABEN The invention contemplates a composition containing a multispecific ligand containing at least a first ligand binding moiety and a second ligand binding moiety. The first ligand binding moiety specifically binds with a pre-selected first affinity to at least a first ligand. The first ligand has a first biodistribution. The second ligand binding moiety specifically binds with a pre-selected affinity to at least a second ligand. The second ligand has a second biodistribution. The affinity of first and second ligand binding moieties are selected to bias the biodistribution of the multispecific ligand in favour of a selected location of one or both of the ligands.

ABFR L'invention concerne une composition qui contient un ligand multispecifique renfermant au moins une premiere fraction de liaison de ligand et une seconde fraction de liaison de ligand. La premiere fraction de liaison de ligand se lie specifiquement avec une premiere affinite preselectionnee a au moins un premier ligand. Le premier ligand possede une premiere biodistribution. La seconde fraction de liaison de ligand se lie specifiquement avec une affinite preselectionnee a au moins un second ligand. Le second ligand possede une seconde biodistribution. Les affinites des premiere et seconde fractions de liaison de ligand sont selectionnees pour influencer la biodistribution du ligand multispecifique en faveur d'un emplacement selectionne de l'un

et/ou l'autre des ligands.

L5 ANSWER 19 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003057711 PCTFULL ED 20030723 EW 200329
TITLE (ENGLISH): ISOLATED CYTOKINE RECEPTOR LICR-2
TITLE (FRENCH): ISOLATION DU RECEPTEUR DE CYTOKINE LICR-2
INVENTOR(S): RENAULD, Jean-Christophe, Avenue Hippocrate 74, UCL 74.59, B-1200 Brussels, BE;
FICKENSICHER, Helmut, Insitut fur Klinische und Molekulare Virologie, Friedrich-Alexander-Universistat, Erlanger-Nurnberg, 91054, DE;
DUMOUTIER, Laure, Avenue Hippocrate 74, UCL 74.59, B-1200 Brussels, BE;
HOR, Simon, Insitut fur Klinische und Molekulare Virologie, Friedrich-Alexander-Universistat, Erlanger-Nurnberg, 91054, DE
PATENT ASSIGNEE(S): LUDWIG INSTITUTE FOR CANCER RESEARCH, 605 Third Avenue, New York, NY 10158, US [US, CH]
AGENT: HANSON, Norman, D.$, Fulbright & Jaworski L.L.P., 666 Fifth Avenue, New York, NY 10103$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003057711	**A2**	**20030717**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-US39231 A 20021209
PRIORITY INFO.: 2001-10/026,106 20011221
US 2001-10/026,106 20011221

ABEN The invention relates to new members of the Class II cytokine receptor family, such as LICR-2. The new member binds to AK155, and mediates STAT activation.
ABFR La presente invention concerne de nouveaux membres de la famile des recepteurs de cytokine Classe II tels que les LICR-2. Ce nouveau membre, qui se lie a AK155, est mediateur pour l'activation du signal STAT.

L5 ANSWER 20 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003042661 PCTFULL ED 20030530 EW 200321
TITLE (ENGLISH): METHODS OF DIAGNOSIS OF CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF CANCER
TITLE (FRENCH): METHODES DE DIAGNOSTIC DU CANCER, COMPOSITIONS ET METHODES DE CRIBLAGE DES MODULATEURS DU CANCER
INVENTOR(S): AFAR, Daniel, 435 Visitacion Avenue, Brisbane, CA 94005, US [CA, US];
AZIZ, Natasha, 411 California Avenue, Palo Alto, CA 94306, US [US, US];
GINSBURG, Wendy, M., 655 Page Street, San Francisco, CA 94117, US [US, US];
GISH, Kurt, C., 37 Artuna Avenue, Piedmont, CA 94611, US [US, US];

GLYNNE, Richard, 2691 Palomino Circle, La Jolla, CA 92037, US [GB, US];
HEVEZI, Peter, A., 1360 11th Avenue, San Francisco, CA 94122, US [GB, US];
MACK, David, H., 2076 Monterey Avenue, Menlo Park, CA 94025, US [US, US];
MURRAY, Richard, 22643 Woodridge Court, Cupertino, CA 95014, US [US, US];
WATSON, Susan, R., 805 Balra Drive, El Cerrito, CA 94530, US [GB, US];
WILSON, Keith, E., 219 Jeter Street, Redwood City, CA 94062, US [US, US];
ZLOTNIK, Albert, 507 Alger Drive, Palo Alto, CA 94306, US [US, US]

PATENT ASSIGNEE(S): EOS BIOTECHNOLOGY, INC., 225A Gateway Boulevard, South San Francisco, CA 94080, US [US, US], for all designates States except US;
AFAR, Daniel, 435 Visitacion Avenue, Brisbane, CA 94005, US [CA, US], for US only;
AZIZ, Natasha, 411 California Avenue, Palo Alto, CA 94306, US [US, US], for US only;
GINSBURG, Wendy, M., 655 Page Street, San Francisco, CA 94117, US [US, US], for US only;
GISH, Kurt, C., 37 Artuna Avenue, Piedmont, CA 94611, US [US, US], for US only;
GLYNNE, Richard, 2691 Palomino Circle, La Jolla, CA 92037, US [GB, US], for US only;
HEVEZI, Peter, A., 1360 11th Avenue, San Francisco, CA 94122, US [GB, US], for US only;
MACK, David, H., 2076 Monterey Avenue, Menlo Park, CA 94025, US [US, US], for US only;
MURRAY, Richard, 22643 Woodridge Court, Cupertino, CA 95014, US [US, US], for US only;
WATSON, Susan, R., 805 Balra Drive, El Cerrito, CA 94530, US [GB, US], for US only;
WILSON, Keith, E., 219 Jeter Street, Redwood City, CA 94062, US [US, US], for US only;
ZLOTNIK, Albert, 507 Alger Drive, Palo Alto, CA 94306, US [US, US], for US only

AGENT: BASTIAN, Kevin, L.$, Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eighth Floor, San Francisco, CA 94111$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003042661	**A2**	**20030522**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US36810 A 20021113

PRIORITY INFO.: 2001-60/350,666 20011113
US 2001-60/350,666 20011113
US 2001-60/332,464 20011121
US 2001-60/332,464 20011121
US 2001-60/334,393 20011129
US 2001-60/334,393 20011129
US 2001-60/335,394 20011203
US 2001-60/335,394 20011203
US 2001-60/340,376 20011214
US 2001-60/340,376 20011214
US 2002-60/347,211 20020108
US 2002-60/347,211 20020108
US 2002-60/347,349 20020110
US 2002-60/347,349 20020110
US 2002-60/347,349 20020208
US 2002-60/347,349 20020208
US 2002-60/356,714 20020213
US 2002-60/356,714 20020213
US 2002-60/359,077 20020220
US 2002-60/359,077 20020220
US 2002-60/368,809 20020329
US 2002-60/368,809 20020329
US 2002-60/370,110 20020404
US 2002-60/370,110 20020404
US 2002-60/372,246 20020412
US 2002-60/372,246 20020412
US 2002-60/386,614 20020605
US 2002-60/386,614 20020605
US 2002-60/396,839 20020716
US 2002-60/396,839 20020716
US 2002-60/397,775 20020722
US 2002-60/397,775 20020722
US 2002-60/397,845 20020722
US 2002-60/397,845 20020722
US 2002-60/409,450 20020909
US 2002-60/409,450 20020909

ABEN Described herein are genes whose expression are up-regulated or down-regulated in specific cancers or other diseases, or are otherwise regulated in disease. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions.

ABFR Cette invention concerne des genes dont l'expression est regulee positivement ou negativement dans certains cancers ou pathologies specifiques, ou bien dont l'expression est regulee dans les etats pathologiques. Sont egalement decrites des methodes et des compositions connexes convenant pour le diagnostic, le pronostic et le traitement de ces pathologie ainsi que ces methodes permettant d'identifier les modulateurs de ces dernieres.

L5 ANSWER 21 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003040345 PCTFULL ED 20030520 EW 200320
TITLE (ENGLISH): TYPE 2 CYTOKINE RECEPTOR AND NUCLEIC ACIDS ENCODING SAME
TITLE (FRENCH): RECEPTEUR DE CYTOKINE DE TYPE 2 ET ACIDES NUCLEIQUES CODANT CE DERNIER
INVENTOR(S): LIU, Wei, 266 Grove Street, #6, Auburndale, MA 02466, US [CN, US];
FOUSER, Lynette, 57 Hampton Street, Acton, MA 01720, US [US, US];
SPAULDING, Vikki, P.O. Box 1243, East Hampstead, NH 03826, US [US, US]

PATENT ASSIGNEE(S): WYETH, Five Giralda Farms, Madison, NJ 07940, US [US, US], for all designates States except US;
LIU, Wei, 266 Grove Street, #6, Auburndale, MA 02466, US [CN, US], for US only;
FOUSER, Lynette, 57 Hampton Street, Acton, MA 01720, US [US, US], for US only;
SPAULDING, Vikki, P.O. Box 1243, East Hampstead, NH 03826, US [US, US], for US only

AGENT: ELRIFI, IVOR, R.$, Mintz, Levin, Cohn, Ferris,, Glovsky and Popeo, PC, One Financial Center, Boston, MA 02111$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003040345	**A2**	**20030515**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US36316 A 20021112
PRIORITY INFO.: 2001-60/332,366 20011109
US 2001-60/332,366 20011109

ABEN The present invention provides novel isolated CRF2-13 polynucleotides and polypeptides encoded by the CRF2-13 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-13 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the CRF2-13 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the CRF2-13 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

ABFR La presente invention concerne de nouveaux polynucleotides isoles CRF2-13 et des polypeptides codes par lesdits polynucleotides CRF2-13; des anticorps qui se lient de maniere immunospecifique a un polypeptide CRF2-13 ou a n'importe quel derive (y compris un derive de fusion), variant, mutant ou fragment du polypeptide, polynucleotide ou anticorps CRF2-13. Cette invention concerne egalement des methodes dans lesquelles on utilise le polypeptide, le polynucleotide ou l'anticorps CRF2-13 pour detecter et traiter une grande diversite d'etats pathologiques, ainsi que d'autres utilisations de ces derniers.

L5 ANSWER 22 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003028630 PCTFULL ED 20030416 EW 200315
TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR MODULATING INTERLEUKIN-21 RECEPTOR ACTIVITY
TITLE (FRENCH): PROCEDES ET COMPOSITIONS PERMETTANT DE MODULER L'ACTIVITE DU RECEPTEUR DE L'INTERLEUKINE-21
INVENTOR(S): CARTER, Laura, 58 Mystic Street, Medford, MA 02155, US [US, US];
WHITTERS, Matthew, J., 14 Brenton Wood Road, Hudson, MA 01749, US [US, US];
COLLINS, Mary, 54 Rathbun Road, Natick, MA 01760, US

[US, US];
YOUNG, Deborah, A., 39 Nelson Road, Melrose, MA 02176, US [US, US];
LARSEN, Glenn, 112 Maynard Farm Road, Sudbury, MA 01776, US [US, US];
DONALDSON, Debra, D., 108 Blakely Road, Medford, MA 02155, US [US, US];
LOWE, Leslie, D., 167 Pratts Mill Road, Sudbury, MA 01776, US [US, US];
DUNUSSI, Kyri, 64 Douglas Road, Belmont, MA 02478, US [—, US];
MA, Margery, 4925 Washington St., #403, West Roxbury, MA 02132, US [—, US];
WITEK, JoAnn, S., 409 Arlington Street, Acton, MA 01720, US [US, US];
KASAIAN, Marion, T., 18 Concord Street, #1, Charleston, MA 02129, US [US, US];
UNGAR, Michelle, 4 Ayr Rd., #31, Brigthon, MA 02135, US [US, US]

PATENT ASSIGNEE(S): WYETH, 87 Cambridge Park Drive, Cambridge, MA 02140, US [US, US], for all designates States except US;
CARTER, Laura, 58 Mystic Street, Medford, MA 02155, US [US, US], for US only;
WHITTERS, Matthew, J., 14 Brenton Wood Road, Hudson, MA 01749, US [US, US], for US only;
COLLINS, Mary, 54 Rathbun Road, Natick, MA 01760, US [US, US], for US only;
YOUNG, Deborah, A., 39 Nelson Road, Melrose, MA 02176, US [US, US], for US only;
LARSEN, Glenn, 112 Maynard Farm Road, Sudbury, MA 01776, US [US, US], for US only;
DONALDSON, Debra, D., 108 Blakely Road, Medford, MA 02155, US [US, US], for US only;
LOWE, Leslie, D., 167 Pratts Mill Road, Sudbury, MA 01776, US [US, US], for US only;
DUNUSSI, Kyri, 64 Douglas Road, Belmont, MA 02478, US [—, US], for US only;
MA, Margery, 4925 Washington St., #403, West Roxbury, MA 02132, US [—, US], for US only;
WITEK, JoAnn, S., 409 Arlington Street, Acton, MA 01720, US [US, US], for US only;
KASAIAN, Marion, T., 18 Concord Street, #1, Charleston, MA 02129, US [US, US], for US only;
UNGAR, Michelle, 4 Ayr Rd., #31, Brigthon, MA 02135, US [US, US], for US only

AGENT: COLLAZO, Diana, M.$, Wyeth, 5 Giralda Farms, Madison, NJ 079040$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003028630	**A2**	**20030410**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-US29839 A 20021004
PRIORITY INFO.: 2001-09/972,218 20011004
US 2001-09/972,218 20011004
US 2002-60/373,746 20020417
US 2002-60/373,746 20020417

ABEN Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (IL-21R or MU-1), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

ABFR L'invention concerne des procedes et des compositions permettant de moduler l'interleukine-21 (IL-21)/le recepteur de l'IL-21 (MU-1) par le biais d'agonistes ou d'antagonistes vis-a-vis de l'IL-21 ou du recepteur de l'IL-21 (IL-21R ou MU-1). On peut utiliser des antagonistes vis-a-vis de l'IL-21/IL-21R afin d'induire une immunosuppression in vivo, par exemple pour le traitement ou la prevention de pathologies associees aux cellules immunitaires (entre autres, pathologies associees a une activite aberrante d'une ou plusieurs cellules comme les lymphocytes T murs (lymphocytes T murs CD8+, CD4+ T), les cellules NK mures, les lymphocytes B, les macrophages et les megacaryocytes, y compris le rejet du greffon et les maladies autoimmunes). Les agonistes vis-a-vis de l'IL-21/IL-21R peuvent etre utilises seuls ou en combinaison avec un antigene, par exemple sous forme d'adjuvant (notamment, adjuvant de vaccin), pour la regulation positive de reaction immune in vivo, entre autres dans le traitement du cancer et des maladies infectieuses.

L5 ANSWER 23 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2003025138 PCTFULL ED 20030402 EW 200313
TITLE (ENGLISH): METHODS OF DIAGNOSIS OF CANCER COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF CANCER
TITLE (FRENCH): PROCEDES DE DIAGNOSTIC DU CANCER, COMPOSITIONS ET PROCEDES DE CRIBLAGE DE MODULATEURS DU CANCER
INVENTOR(S): AFAR, Daniel, 435 Visitacion Avenue, Brisbane, CA 94005, US [CA, US];
AZIZ, Natasha, 411 California Avenue, Palo Alto, CA 94306, US [US, US];
GISH, Kurt, C., 37 Artuna Avenue, Piedmont, CA 94611, US [US, US];
HEVEZI, Peter, A., 1360 11th Avenue, San Francisco, CA 94122, US [GB, US];
MACK, David, H., 2076 Monterey Avenue, Menlo Park, CA 94025, US [US, US];
WILSON, Keith, E., 219 Jeter Street, Redwood City, CA 94062, US [US, US];
ZLOTNIK, Albert, 507 Alger Drive, Palo Alto, CA 94306, US [US, US]
PATENT ASSIGNEE(S): EOS BIOTECHNOLOGY, INC., 225A Gateway, Boulevard, South San Francisco, CA 94080, US [US, US], for all designates States except US;
AFAR, Daniel, 435 Visitacion Avenue, Brisbane, CA 94005, US [CA, US], for US only;
AZIZ, Natasha, 411 California Avenue, Palo Alto, CA

94306, US [US, US], for US only;
GISH, Kurt, C., 37 Artuna Avenue, Piedmont, CA 94611, US [US, US], for US only;
HEVEZI, Peter, A., 1360 11th Avenue, San Francisco, CA 94122, US [GB, US], for US only;
MACK, David, H., 2076 Monterey Avenue, Menlo Park, CA 94025, US [US, US], for US only;
WILSON, Keith, E., 219 Jeter Street, Redwood City, CA 94062, US [US, US], for US only;
ZLOTNIK, Albert, 507 Alger Drive, Palo Alto, CA 94306, US [US, US], for US only

AGENT: BASTIAN, Kevin, L.$, Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eighth Floor, San Francisco, CA 94111$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2003025138	**A2**	**20030327**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2002-US29560 A 20020917
PRIORITY INFO.: 2001-60/323,469 20010917
US 2001-60/323,469 20010917
US 2001-60/323,887 20010920
US 2001-60/323,887 20010920
US 2001-60/350,666 20011113
US 2001-60/350,666 20011113
US 2002-60/355,145 20020208
US 2002-60/355,145 20020208
US 2002-60/355,257 20020208
US 2002-60/355,257 20020208
US 2002-60/372,246 20020412
US 2002-60/372,246 20020412

ABEN Described herein are genes whose expression are up-regulated or down-regulated in specific cancers. Related methods and compositions that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.

ABFR L'invention concerne des genes dont l'expression est regulee positivement ou negativement dans des cancers specifiques ; des procedes et des compositions associees pouvant servir a diagnostiquer et a traiter ces cancers ; et des procedes pouvant servir a identifier des modulateurs de cancers selectionnes.

L5 ANSWER 24 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2002072141 PCTFULL ED 20020927 EW 200238
TITLE (ENGLISH): TARGETED LIGANDS
TITLE (FRENCH): LIGANDS CIBLES
INVENTOR(S): HERMAN, William, 18 Gailerest Circle, Thornhill, Ontario L4J 5Y2, CA [CA, CA]

PATENT ASSIGNEE(S): HERMAN, William, 18 Gailerest Circle, Thornhill, Ontario L4J 5Y2, CA [CA, CA]
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002072141	**A2**	**20020919**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2002-CA317	A	20020311
PRIORITY INFO.:	2001-60/274,217		20010309
	US 2001-60/274,217		20010309
	US 2001-60/276,911		20010320
	US 2001-60/276,911		20010320
	US 2001-60/279,132		20010328
	US 2001-60/279,132		20010328
	US 2001-60/281,029		20010407
	US 2001-60/281,029		20010407
	US 2001-60/306,148		20010719
	US 2001-60/306,148		20010719
	US 2002-2,368,708		20020114
	CA 2002-2,368,708		20020114

ABEN The invention contemplates a composition containing a multispecific ligand containing at least a first ligand binding moiety and a second ligand binding moiety. The first ligand binding moiety specifically binds with a pre-selected first affinity to at least a first ligand. The first ligand has a first biodistribution. The second ligand binding moiety specifically binds with a pre-selected affinity to at least a second ligand. The second ligand has a second biodistribution. The affinity of first and second ligand binding moieties are selected to bias the biodistribution of the multispecific ligand in favour of a selected location of one or both of the ligands.

ABFR Cette invention se rapporte a une composition contenant un ligand multispecifique renfermant au moins une premiere fraction de fixation de ligand et une seconde fraction de fixation de ligand. La premiere fraction de fixation de ligand se fixe specifiquement avec une premiere affinite preselectionnee a au moins un premier ligand. Ce premier ligand possede une premiere biodistribution. La seconde fraction de fixation de ligand se fixe specifiquement avec une affinite preselectionnee a au moins un second ligand. Ce second ligand possede une seconde biodistribution. Les affinites des premiere et seconde fractions de fixation de ligand sont choisies pour biaiser la biodistribution du ligand multispecifique en faveur d'une position selectionnee de l'un et/ou l'autre des ligands.

L5 ANSWER 25 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2002070001 PCTFULL ED 20020926 EW 200237
TITLE (ENGLISH): USE OF LP82 TO TREAT HEMATOPOIETIC DISORDERS
TITLE (FRENCH): UTILISATION DE LP82 POUR TRAITER LES TROUBLES HEMATOPOIETIQUES
INVENTOR(S): LIU, Ling, 10740 Putnam Place, Carmel, IN 46032, US

[CA, US];
HEUER, Josef, Georg, 651 Sunbeam Circle, Indianapolis, IN 46231, US [US, US];
NOBLITT, Timothy, Wayne, 11515 Charleston Parkway, Fishers, IN 46038, US [US, US]

PATENT ASSIGNEE(S): ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, IN 46285, US [US, US], for all designates States except US;
LIU, Ling, 10740 Putnam Place, Carmel, IN 46032, US [CA, US], for US only;
HEUER, Josef, Georg, 651 Sunbeam Circle, Indianapolis, IN 46231, US [US, US], for US only;
NOBLITT, Timothy, Wayne, 11515 Charleston Parkway, Fishers, IN 46038, US [US, US], for US only

AGENT: WISKERCHEN, MaryAnn$, ELI LILLY AND COMPANY, Lilly Corporate Center, Indianapolis, IN 46285$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002070001	**A2**	**20020912**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2002-US3377	A	20020214
PRIORITY INFO.:	2001-60/272,242		20010228
	US 2001-60/272,242		20010228
	US 2001-60/332,740		20011119
	US 2001-60/332,740		20011119
	US 2002-60/353,789		20020201
	US 2002-60/353,789		20020201

ABEN The present invention relates to a method of using a mammalian gene sequence and polypeptides encoded thereby to treat mammalian hematopoietic disorders. More specifically the present invention relates to methods of using compositions comprising at least one LP82 agonist, LP82 antagonist, LP82 polynucleotide, LP82 polypeptide, and/or LP82 antibody for the prevention and/or treatment of mammalian hematopoietic disorders, including, but not limited to, anemia, leukemia, and hematopoietic conditions caused by bone marrow transplantation or chemo-/radiation therapy.

ABFR L'invention concerne une methode d'utilisation d'une sequence genetique mammifere et des polypeptides codees par celle-ci pour traiter les troubles hematopoietiques chez les mammiferes. Plus precisement, l'invention concerne des methodes d'utilisation de compositions contenant au moins un agoniste de LP82, un antagoniste de LP82, un polynucleotide de LP82, un polypeptide de LP82, et/ou un anticorps de LP82 pour prevenir et/ou traiter des troubles hematopoietiques chez les mammiferes, notamment l'anemie, la leucemie, et les etats hematopoietiques induits par une greffe de moelle osseuse ou par la chimiotherapie/radiotherapie.

L5 ANSWER 26 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN

ACCESSION NUMBER: 2002066647 PCTFULL ED 20020910 EW 200235
TITLE (ENGLISH): TYPE 2 CTOKINE RECEPTOR AND NUCLEIC ACIDS ENCODING SAME
TITLE (FRENCH): RECEPTEUR DE CYTOKINE DE TYPE 2 ET ACIDES NUCLEIQUES CODANT CE RECEPTEUR
INVENTOR(S): FOUSER, Lynette, 57 Hampton Street, Acton, MA 01720, US [US, US];
LIU, Wei, 266 Grove Street, #6, Auburndale, MA 02466, US [CN, US];
DENG, Bijia, 38 Coolidge Road, Allston, MA 02134, US [US, US]
PATENT ASSIGNEE(S): GENETICS INSTITUTE, LLC, 87 CambridePark Drive, Cambridge, MA 02140, US [US, US], for all designates States except US;
FOUSER, Lynette, 57 Hampton Street, Acton, MA 01720, US [US, US], for US only;
LIU, Wei, 266 Grove Street, #6, Auburndale, MA 02466, US [CN, US], for US only;
DENG, Bijia, 38 Coolidge Road, Allston, MA 02134, US [US, US], for US only
AGENT: ELRIFI, Ivor, R.$, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C, ., One Fiancial Center, Boston, MA 02111$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002066647	**A2**	**20020829**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2002-US986	A 20020114
PRIORITY INFO.:	2001-60/261,442	20010112
	US 2001-60/261,442	20010112
	US 2001-60/267,021	20010206
	US 2001-60/267,021	20010206
	US 2001-60/270,835	20010223
	US 2001-60/270,835	20010223

ABEN The present invention provides novel isolated CRF2-12 polynucleotides and polypeptides encoded by the CRF2-12 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-12 polypeptide or any derivative (including fusion derivative), variant, mutant of the CRF2-12 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the CRF2-12 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

ABFR La presente invention concerne de nouveaux polynucleotides et polypeptides de la famille des recepteurs de cytokine de type 2-12 isoles, codes par les polynucleotides de la famille des recepteurs de cytokine de type 2-12. L'invention concerne egalement les anticorps qui se fixent de maniere immunospecifique a un polypeptide de la famille des recepteurs de cytokine ou a n'importe quel derive (y compris un derive de fusion), allele, mutant ou fragment du polypeptide, du polynucleotide

ou de l'anticorps de la famille des recepteurs de cytokine de type 2-12. L'invention concerne enfin des methodes selon lesquelles le polypeptide, le polynucleotide ou l'anticorps de la famille des recepteurs de cytokine de type 2-12 sont utilises dans la detection et le traitement d'une large gamme d'etats pathologiques, ainsi qu'a d'autres fins.

L5 ANSWER 27 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2002066600 PCTFULL ED 20020910 EW 200235
TITLE (ENGLISH): METHODS AND MATERIALS RELATING TO LEUKOCYTE IMMUNOGLOBULIN RECEPTOR-LIKE (LIR-LIKE) POLYPEPTIDES AND POLYNUCLEOTIDES
TITLE (FRENCH): PROCEDES ET MATERIAUX CONCERNANT DES POLYPEPTIDES ET POLYNUCLEOTIDES SEMBLABLES A DES RECEPTEURS DE LEUCOCYTES DE TYPE IMMUNOGLOBULINE (LIR)
INVENTOR(S): BOYLE, Bryan, J., 1947 10th Avenue, San Francisco, CA 94116, US [US, US];
KUO, Chiaoyun, 2121 Limewood Drive, San Jose, CA 95132, US [US, US];
MIZE, Nancy, K., 662 Mountain View Avenue, Mountain View, CA 94041, US [US, US];
HALEY-VICENTE, Dana, A., 11917 Meridien Lane, San Diego, CA 92128, US [US, US];
ARTERBURN, Matthew, C., 15840 Union Avenue, Los Gatos, CA 95032, US [US, US];
TANG, Y., Tom, 4230 Ranwick Court, San Jose, CA 95118, US [US, US];
ZHOU, Ping, 7595 Newcastle Drive, Cupertino, CA 95014, US [US, US];
LIU, Chenghua, 1125 Ranchero Way #14, San Jose, CA 95117, US [CN, US];
ASUNDI, Vinod, 709 Foster City Boulevard, Foster City, CA 94404, US [US, US];
DRMANAC, Radoje, T., 850 East Greenwich Place, Palo Alto, CA 94303, US [US, US];
YEUNG, George, 102 Magnolia Lane, Mountain View, CA, US [CN, US];
PALENCIA, Servando, 522 Columbia Street, Santa Cruz, CA 95060, US [MX, US]
PATENT ASSIGNEE(S): HYSEQ, INC., 670 Almanor Avenue, Sunnyvalle, CA 94086, US [US, US], for all designates States except US;
BOYLE, Bryan, J., 1947 10th Avenue, San Francisco, CA 94116, US [US, US], for US only;
KUO, Chiaoyun, 2121 Limewood Drive, San Jose, CA 95132, US [US, US], for US only;
MIZE, Nancy, K., 662 Mountain View Avenue, Mountain View, CA 94041, US [US, US], for US only;
HALEY-VICENTE, Dana, A., 11917 Meridien Lane, San Diego, CA 92128, US [US, US], for US only;
ARTERBURN, Matthew, C., 15840 Union Avenue, Los Gatos, CA 95032, US [US, US], for US only;
TANG, Y., Tom, 4230 Ranwick Court, San Jose, CA 95118, US [US, US], for US only;
ZHOU, Ping, 7595 Newcastle Drive, Cupertino, CA 95014, US [US, US], for US only;
LIU, Chenghua, 1125 Ranchero Way #14, San Jose, CA 95117, US [CN, US], for US only;
ASUNDI, Vinod, 709 Foster City Boulevard, Foster City, CA 94404, US [US, US], for US only;
DRMANAC, Radoje, T., 850 East Greenwich Place, Palo Alto, CA 94303, US [US, US], for US only;
YEUNG, George, 102 Magnolia Lane, Mountain View, CA, US [CN, US], for US only;

PALENCIA, Servando, 522 Columbia Street, Santa Cruz, CA 95060, US [MX, US], for US only

AGENT: ELRIFI, Ivor, R.$, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC, One Financial Center, Boston, MA 02111$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002066600	**A2**	**20020829**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US49435 A 20011228
PRIORITY INFO.: 2000-09/751,518 20001229
US 2000-09/751,518 20001229

ABEN The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted leukocyte immunoglobulin receptor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from a cDNA library prepared from human leukocyte mRNA (GIBCO Laboratories) (SEQ ID NO: 1, SEQ ID NO: 16); from infant brain mRNA (Columbia University) (SEQ ID NO: 35); from human mammary gland mRNA (Invitrogen) (SEQ ID NO: 47); and from bone marrow mRNA (Clontech) (SEQ ID NO: 63). Other aspects of the invention include vectors containing processes for producing novel human secreted LIR-like polypeptides, and antibodies specific for such polypeptides.

ABFR L'invention concerne de nouveaux polynucleotides et des polypeptides codes par lesdits polynucleotides ainsi que leurs mutants ou variants qui correspondent a un nouveau polypeptide humain secrete semblable a un recepteur de leucocyte de type immunoglobuline. Ces polynucleotides renferment des sequences d'acide nucleique isolees de banques d'ADNc preparees a partir d'une banque d'ADNc preparee a partir d'un ARNm de leucocyte humain (Laboratoires GIBCO) (SEQ ID NO:1, SEQ ID NO:16); d'un ARNm du cerveau d'un nourrisson (Columbia University) (SEQ ID NO: 35); d'un ARNm de glande mammaire humaine (Invitrogene) (SEQ ID NO: 47); et d'un ARNm de moelle osseuse (Clontech) (SEQ ID NO: 63). D'autres aspects de l'invention concernent des vecteurs contenant des procedes de production de polypeptides humains secretes semblables a LIR, ainsi que des anticorps propres a ces polypeptides.

L5 ANSWER 28 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2002057414 PCTFULL ED 20020801 EW 200230
TITLE (ENGLISH): LEUKOCYTE EXPRESSION PROFILING
TITLE (FRENCH): EVALUATION DU NIVEAU D'EXPRESSION LEUCOCYTAIRE
INVENTOR(S): WOHLGEMUTH, Jay, 664 Hamilton Avenue, Palo Alto, CA 94301, US [US, US];
FRY, Kirk, 2604 Ross Road, Palo Alto, CA 94303, US [US, US];
MATCUK, George, 141C Escondido Village, Stanford, CA 94305, US [US, US];
ALTMAN, Peter, 717 Evelyn Avenue, Albany, CA 94706, US

[US, US];
PRENTICE, James, 120 Dolores Street, San Francisco, CA 94103, US [US, US];
PHILLIPS, Julie, 1090 Mirador Terrace, Pacifica, CA 94044, US [US, US];
LY, Ngoc, 2000 Crystal Springs Road 15-14, San Bruno, CA 94066, US [US, US];
WOODWARD, Robert, 1828 Rheem Court, Pleasanton, CA 94588, US [US, US];
QUERTERMOUS, Thomas, 44 El Rey Road, Portola Valley, CA 94028, US [US, US];
JOHNSON, Frances, 44 El Rey Road, Portola Valley, CA 94028, US [US, US]

PATENT ASSIGNEE(S): BIOCARDIA, INC., 384 Oyster Point Boulevard, #4, South San Francisco, CA 94080, US [US, US], for all designates States except US;
WOHLGEMUTH, Jay, 664 Hamilton Avenue, Palo Alto, CA 94301, US [US, US], for US only;
FRY, Kirk, 2604 Ross Road, Palo Alto, CA 94303, US [US, US], for US only;
MATCUK, George, 141C Escondido Village, Stanford, CA 94305, US [US, US], for US only;
ALTMAN, Peter, 717 Evelyn Avenue, Albany, CA 94706, US [US, US], for US only;
PRENTICE, James, 120 Dolores Street, San Francisco, CA 94103, US [US, US], for US only;
PHILLIPS, Julie, 1090 Mirador Terrace, Pacifica, CA 94044, US [US, US], for US only;
LY, Ngoc, 2000 Crystal Springs Road 15-14, San Bruno, CA 94066, US [US, US], for US only;
WOODWARD, Robert, 1828 Rheem Court, Pleasanton, CA 94588, US [US, US], for US only;
QUERTERMOUS, Thomas, 44 El Rey Road, Portola Valley, CA 94028, US [US, US], for US only;
JOHNSON, Frances, 44 El Rey Road, Portola Valley, CA 94028, US [US, US], for US only

AGENT: WARD, Michael, R.$, Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002057414	**A2**	**20020725**

DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US47856 A 20011022

PRIORITY INFO.: 2000-60/241,994 20001020
US 2000-60/241,994 20001020
US 2001-60/296,764 20010608
US 2001-60/296,764 20010608

ABEN Leukocyte gene expression profiling is utilized to identify

oligonucleotides from gene expression candidate libraries. The expression libraries are generally immobilized on an array. Diagnostic oligonucleotide sets for analysis of leukocyte-related diseases are described.

ABFR L'invention concerne l'evaluation du niveau d'expression genique d'un leucocyte utilise pour identifier des oligonucleotides a partir de bibliotheques candidates d'expression genique. Ces bibliotheques d'expression sont generalement immobilisees sur une matrice. L'invention concerne egalement un oligonucleotide de diagnostic regle de facon a analyser des maladies associees a un leucocyte.

L5 ANSWER 29 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2001066107 PCTFULL ED 20020822
TITLE (ENGLISH): TREATMENT OF DISEASES ASSOCIATED WITH CYTOKINE PRODUCTION WITH INHIBITORS OF THE TEC FAMILY OF PROTEIN TYROSINE KINASES
TITLE (FRENCH): AGENT UTILISE DANS UN PROCEDE DE TRAITEMENT
INVENTOR(S): FOXWELL, Brian, Maurice, John
PATENT ASSIGNEE(S): THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY TRUST;
FOXWELL, Brian, Maurice, John
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001066107	**A2**	**20010913**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-GB949	A 20010306
PRIORITY INFO.:	2000-0005345.4	20000306
	GB 2000-0005345.4	20000306

ABEN The present invention relates to a method of treating a condition comprising administering a pharmaceutically effective amount of an inhibitor of the Tec family of protein tyrosine kinases (PTKs). The condition is typically associated with cytokine production. Conditions addressed by the invention include sepsis, septic shock, inflammation, rheumatoid arthritis and Crohn's disease. In one embodiment, the condition is induced by zymosan. The invention also provides the use of an inhibitor of a member or members of the Tec family of PTKs in the manufacture of a medicament for use in the treatment of a condition associated with cytokine production and methods for identifying an inhibitor of a member or members of the Tec family of PTKs which is also suitable for use in the treatment of a condition associated with stimulus-induced cytokine production.

ABFR L'invention concerne un procede pour traiter un etat qui consiste a administrer au patient une quantite pharmaceutiquement efficace d'un inhibiteur de la famille Tec des proteines tyrosines kinases (PTK), l'etat en question etant normalement associe a la production de cytokines. Les etats que concerne l'invention comprennent la septicemie, le choc septique, l'inflammation, l'arthrite rhumatoide et la maladie de Crohn. Dans un mode de realisation, cet etat est provoque par le zymosan. L'invention concerne aussi l'utilisation d'un inhibiteur d'un ou de plusieurs elements de la famille des PTK dans la fabrication d'un medicament destine a etre utilise dans le traitement d'un etat associe a la production de cytokines et des procedes pour identifier un inhibiteur

d'un ou de plusieurs elements de la famille des PTK, qui convient aussi pour le traitement d'un etat associe a la production de cytokines induite par de stimulus.

L5 ANSWER 30 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2001064834 PCTFULL ED 20020822
TITLE (ENGLISH): NOVEL NUCLEIC ACIDS AND POLYPEPTIDES
TITLE (FRENCH): NOUVEAUX ACIDES NUCLEIQUES ET POLYPEPTIDES
INVENTOR(S): TANG, Y, Tom;
LIU, Chenghua;
ZHOU, Ping;
ASUNDI, Vinod;
ZHANG, Jie;
ZHAO, Qing, A.;
REN, Feiyan;
XUE, Aidong, J.;
YANG, Yonghong;
WEHRMAN, Tom;
WANG, Jian-Rui;
MA, Yunqing;
WANG, Dunrui;
CHEN, Rui-hong;
XU, Chongjun;
DRMANAC, Radoje
PATENT ASSIGNEE(S): HYSEQ, INC.;
TANG, Y, Tom;
LIU, Chenghua;
ZHOU, Ping;
ASUNDI, Vinod;
ZHANG, Jie;
ZHAO, Qing, A.;
REN, Feiyan;
XUE, Aidong, J.;
YANG, Yonghong;
WEHRMAN, Tom;
WANG, Jian-Rui;
MA, Yunqing;
WANG, Dunrui;
CHEN, Rui-hong;
XU, Chongjun;
DRMANAC, Radoje
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001064834	**A2**	**20010907**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-US4926	A 20010226
PRIORITY INFO.:	2000-09/515,126	20000228
	US 2000-09/515,126	20000228
	US 2000-09/577,409	20000518
	US 2000-09/577,409	20000518
	US 2000-09/597,707	20000617
	US 2000-09/597,707	20000617

US 2000-09/616,807 20000714
US 2000-09/616,807 20000714
US 2000-09/664,641 20000919
US 2000-09/664,641 20000919

ABEN
ABFR La presente invention concerne de nouveaux acides nucleiques, de nouvelles sequences polypeptidiques codees par lesdits acides nucleiques et leurs utilisations.

L5 ANSWER 31 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2001054721 PCTFULL ED 20020827
TITLE (ENGLISH): ANTAGONIST OF TH-1 IMMUNERESPONSE INDUCING CYTOKINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
TITLE (FRENCH): ANTAGONISTES DE REPONSE IMMUNITAIRE TH-1 EMPLOYANT LA CYTOKINE DANS LE TRAITEMENT DE MALADIES AUTO-IMMUNES
INVENTOR(S): TOVEY, Michael, Gerard
PATENT ASSIGNEE(S): PHARMA PACIFIC PTY LTD;
TOVEY, Michael, Gerard
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001054721	**A1**	**20010802**

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-GB285 A 20010125
PRIORITY INFO.: 2000-0001710.3 20000125
GB 2000-0001710.3 20000125
ABEN Oromucosal administration of antagonists of cytokines associated with stimulation or enhancement of T helper 1 cell responses, preferably for example a Type 1-interferon antibody, is disclosed for inhibition of prevention of autoimmune diseases.
ABFR L'invention concerne l'administration par voie orale et muqueuse d'antagonistes de cytokines associes a une stimulation ou un renforcement des reactions des cellules de type 1 (Th1), par exemple, de preference, un anticorps interferon de type 1 afin de prevenir les affections auto-immunes.

L5 ANSWER 32 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2000073257 PCTFULL ED 20020515
TITLE (ENGLISH): DERIVATIVES OF BUTYRIC ACID AND USES THEREOF
TITLE (FRENCH): DERIVES D'ACIDE BUTYRIQUE ET SES UTILISATIONS
INVENTOR(S): GILBERT, Kathleen;
FIFER, E., KimRP : ADLER, Benjamin, A.
PATENT ASSIGNEE(S): THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000073257	**A1**	**20001207**

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT

RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA
ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD
TG

APPLICATION INFO.: WO 2000-US14523 A 20000526
PRIORITY INFO.: 1999-60/136,579 19990528
US 1999-60/136,579 19990528

ABEN The present invention provides a series of compounds having structural formulas (I), (II), (III), (IV) wherein n¿1 is 1 to 5, n¿2 is 1 to 4 and m is 1 to 3; X is O or NH; Y is CH2, O, S, NH, NR; R is selected from the group consisting a straight-chain aliphatic group, a branched-chain aliphatic group and an alicyclic group; wherein R' is selected from the group consisting of hydrogen, methyl and ethyl; when Y is O, n¿1 is not 1; and wherein X and R' are independently optionally substituted at C2, C3 or C4 in compounds of Formula (IV) or a pharmaceutically acceptable salt thereof. Also provided is a method of inactivating antigen-specific T cells in an individual.

ABFR La presente invention concerne une serie de composes de formules (I), (II), (III), (IV) dans lesquelles n¿1 est compris entre 1 et 5, n¿2 est compris entre 1 et 4 et m entre 1 et 3; X represente O ou NH; Y represente CH2, O, S, NH, NR; R est selectionne dans le groupe constitue par un groupe aliphatique a chaine droite, un groupe aliphatique a chaine ramifiee et un groupe alicyclique; R' est selectionne dans le groupe constitue par hydrogene, methyle et ethyle; lorsque Y represente O, n¿1 n'est pas egal a 1; et X et R' sont eventuellement individuellement substitues dans C2, C3 ou C4 des composes de formule (IV), ou un sel de ceux-ci acceptable sur le plan pharmaceutique. En outre, cette invention concerne un procede d'inactivation des cellules T specifiques de l'antigene chez un individu.

L5 ANSWER 33 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1999061617 PCTFULL ED 20020515
TITLE (ENGLISH): INTERLEUKINS-21 AND 22
TITLE (FRENCH): INTERLEUKINE 21 ET 22
INVENTOR(S): RUBEN, Steven, M.;
EBNER, Reinhard
PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;
RUBEN, Steven, M.;
EBNER, Reinhard
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9961617	**A1**	**19991202**

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO
RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA
ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU
TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL

PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 1999-US11644 A 19990527
PRIORITY INFO.: 1998-60/087,340 19980529
US 1998-60/087,340 19980529
US 1998-60/099,805 19980910
US 1998-60/099,805 19980910
US 1999-60/131,965 19990430
US 1999-60/131,965 19990430

ABEN The present invention relates to novel human proteins designated Interleukin-21 (IL-21) and
Interleukin-22 (IL-22), and
isolated polynucleotides encoding these proteins. Also provided are vectors, host cells, **antibodies**, and recombinant methods for producing these human proteins. The
invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating
disorders related to these novel human proteins.

ABFR Nouvelles proteines humaines designees par interleukine 21 (IL-21) et interleukine 22 (IL-22),
et polynucleotides isoles codant ces proteines. Des vecteurs, cellules hotes, anticorps et procedes
de recombinaison destines a la production desdites proteines sont egalement decrits. La presente
invention concerne encore des procedes diagnostiques et therapeutiques utiles pour diagnostiquer et
traiter des troubles associes a ces nouvelles proteines humaines.

L5 ANSWER 34 OF 34 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1994011001 PCTFULL ED 20020513
TITLE (ENGLISH): HYDROXYL-CONTAINING COMPOUNDS
TITLE (FRENCH): COMPOSES A TENEUR HYDROXYLE
INVENTOR(S): UNDERINER, Gail, E.;
PORUBEK, David;
KLEIN, Peter, J.;
WOODSON, Paul
PATENT ASSIGNEE(S): CELL THERAPEUTICS, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9411001	**A1**	**19940526**

DESIGNATED STATES
W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1993-US11226 A 19931116
PRIORITY INFO.: 1992-7/976,353 19921116
US 1992-7/976,353 19921116

ABEN Disclosed are therapeutic compounds having the formula: (R)j - (core moiety), including
resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer
from one to three, the core moiety is either non-cyclic or comprises at least one five- to
seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen,
hydroxyl, amino, substituted or unsubstituted benzyl, C1-6 alkyl or C1-6 alkenyl, and at least one R
has formula (I), wherein n is an integer from seven to twenty and at least one of X or Y is -OH. The
other of X or Y, which is not -OH, is hydrogen, CH3-, CH3-CH2-, CH3-(CH2)2- or (CH3)2-CH2-, and each

W1, W2, and W3 is independently hydrogen, CH3-, CH3-CH2-, CH3-(CH2)2- or (CH3)2-CH2-. The X, Y, W1, W2, or W3 alkyl groups may be unsubstituted or substituted by an hydroxyl, halo or dimethylamino group. The disclosed compounds and therapeutic compositions thereof are useful in treating individuals having a disease or treatment-induced toxicity, mediated by second messenger activity.

ABFR L'invention concerne des composes therapeutiques representes par la formule: (R)j-(fraction noyau), comprenant des enantiomeres dissous, des diastereomeres, des hydrates, des sels, des solvats et leurs melanges. j est un entier entre un et trois, la fraction noyau est soit non cyclique, soit comprend au moins une structure cyclique comportant entre cinq et sept elements, R peut etre selectionne a partir du groupe constitue par hydrogene, halogene, hydroxyle, amino, benzyle substitue ou insubstitute, alkyle C1-6 ou alkenyle C1-6 et au moins un R possede la formule (I), n est un entier entre sept et vingt et au moins un de X ou Y represente -OH. L'autre de X ou Y, qui n'est pas -OH, represente hydrogene, CH3-, CH3-CH2-, CH3-(CH2)2- ou (CH3)2-CH2- et chaque W1, W2 et W3 represente independamment hydrogene, CH3-, CH3-CH2-, CH3-(CH2)2- ou (CH3)2-CH2-. Les groupes alkyle X, Y, W1, W2 ou W3 peuvent etre insubstitues ou substitues par un groupe hydroxyle, halo, ou dimethylamino. Les composes decrits et leurs compositions therapeutiques sont efficaces dans le traitement d'individus atteints d'une maladie ou d'une toxicite provenant d'un traitement provoquee par une activite de deuxieme messager.

=> d his

(FILE 'HOME' ENTERED AT 11:17:36 ON 02 MAR 2005)

FILE 'MEDLINE, SCISEARCH, BIOSIS, CAPLUS, USPATFULL, PCTFULL' ENTERED AT 11:17:56 ON 02 MAR 2005

L1 212 S (ANTIBOD? OR ANTAGONIST? OR BLOCK? OR INHIBIT? OR NEUTRAL?)(S
L2 94 S ((INTERLEUKIN OR IL)(W)22)(P)(ARTHRITI? OR OSTEAOARTHRIT?)
L3 57 S L1 AND L2
L4 51 DUP REM L3 (6 DUPLICATES REMOVED)
L5 34 S L4 AND PY<=2003